Global Authorship Patterns in Phase III Solid-Tumor Trials Presented at the ASCO Annual Meeting, 2015-2025
JCO Oncology Practice · 12.11.2026
DOI: 10.1200/op-26-00529 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 12.11.2026. Verfasst von Azza Sarfraz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Purpose
Authorship of phase III oncology trials reflects broader patterns of scientific leadership, including access to resources, research infrastructure, and global participation. However, how these factors intersect with gender over time remains incompletely characterized. We evaluated trends in authorship across phase III solid-tumor trials presented at the ASCO Annual Meeting from 2015 to 2025.
Methods
We conducted a repeated cross-sectional study of phase III solid-tumor abstracts presented at ASCO (2015-2025). Author gender was assigned using a multistep approach based on publicly available data. Outcomes included authorship by role (first v senior), tumor track, funding source, trial-origin geographic region, and trial-origin World Bank income group. Multivariable logistic regression identified factors associated with female authorship.
Results
Among 1,517 abstracts (3,034 authorships), 27.9% of authors were women. Female authorship increased from 24.9% in 2015-2020 to 30.0% in 2021-2025 ( P = .002). Women were more likely to be first than senior authors (54.7% v 45.3%, P = .002) and were less likely to hold senior authorship overall (adjusted odds ratio [OR], 0.76, 95% CI 0.65-0.90; P = .001). Temporal gains were driven by increased female senior authorship (OR, 1.55 [95% CI, 1.20 to 1.99]; P = .001). Female authorship was lower in several tumor types and in East Asia and Pacific versus North America (OR, 0.65 [95% CI, 0.48 to 0.87]; P = .003). Funding and income group were not associated with female authorship.
Conclusion
Women remain underrepresented in phase III oncology trial authorship, particularly in senior roles and across certain tumor types and regions, suggesting persistent gaps in authorship representation that may reflect broader structural barriers.
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
- Department of Research Administration, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
- Herbert Wertheim College of Medicine, Florida International University, Miami, FL.
- All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, India.
- Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH.
- Department of Neuro-oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
ORCID-Profile: Shree Rath, Sawyer Bawek, Kyaw Lwin Aung, Manmeet Singh Ahluwalia, Sarbajit Mukherjee
Zitieren
APA
Sarfraz, A., Hodgson, L. C., Abraham, S. M., Rath, S., Bawek, S., Aung, K. L., Ahluwalia, M. S., Siromoni, B., & Mukherjee, S. (2026). Global Authorship Patterns in Phase III Solid-Tumor Trials Presented at the ASCO Annual Meeting, 2015-2025. JCO Oncology Practice. https://doi.org/10.1200/op-26-00529
Vancouver
Sarfraz A, Hodgson LC, Abraham SM, Rath S, Bawek S, Aung KL, et al. Global Authorship Patterns in Phase III Solid-Tumor Trials Presented at the ASCO Annual Meeting, 2015-2025. JCO Oncology Practice. 2026. doi:10.1200/op-26-00529
BibTeX
@article{Sarfraz2026,
author = {Sarfraz, Azza and Hodgson, Lydia C and Abraham, Sarah Marie and Rath, Shree and Bawek, Sawyer and Aung, Kyaw Lwin and Ahluwalia, Manmeet Singh and Siromoni, Beas and Mukherjee, Sarbajit},
title = {Global Authorship Patterns in Phase III Solid-Tumor Trials Presented at the ASCO Annual Meeting, 2015-2025},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-26-00529}
}
EUVIMED